Javascript must be enabled to continue!
Biochemical evaluation of Jihua hemostatic suppository in hemorrhagic internal hemorrhoids: Modulation of XPO1, VEGF, and collagen I/III expression and inflammatory biomarkers
View through CrossRef
Background: Hemorrhagic internal hemorrhoids involve abnormal vascular remodeling, inflammatory activation, and extracellular matrix dysregulation. Exportin-1 (Xpo1), vascular endothelial growth factor (VEGF), and collagen types I and III are key biochemical markers associated with these processes. This study aimed to evaluate the therapeutic efficacy of Jihua Hemostatic Suppository compared with Gangtai Suppository and to investigate their differential effects on biochemical and inflammatory parameters in patients with hemorrhagic internal hemorrhoids. Methods: A total of 98 patients diagnosed with hemorrhagic internal hemorrhoids were enrolled between January 2024 and January 2025 and randomly divided into two groups (n = 49 each) using the envelope randomization method. The Jihua group received Jihua Hemostatic Suppository, whereas the control group received Gangtai Suppository for two weeks. Serum levels of interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), and C-reactive protein (CRP) were determined by ELISA. Xpo1 levels were measured by ELISA, VEGF by chemiluminescence assay, and collagen types I and III by the hydroxyproline method. Clinical efficacy, traditional Chinese medicine (TCM) syndrome scores, and adverse reactions were also recorded. Results: The total effective rate in the Jihua group (93.88% ) was significantly higher than that in the Gangtai group (77.55% ) (c2 = 5.968, P = 0.015). After treatment, the Jihua group showed markedly lower serum IL-6 (70.50 ± 5.82 ng/mL), CRP (23.06 ± 2.71 mg/L), and TNF-a (60.81 ± 5.72 ng/mL) levels compared with the Gangtai group (P < 0.001). Biochemically, Xpo1, VEGF, collagen I, and collagen III concentrations were significantly reduced in the Jihua group (12.31 ± 1.35 ng/mL, 389.64 ± 34.32 pg/mL, 154.39 ± 15.19 pg/L, and 36.13 ± 3.06 mg/L, respectively) compared with the Gangtai group (P < 0.05). The incidence of adverse reactions was lower with Jihua suppository (4.08%) than with Gangtai suppository (20.41% ) (c2 = 4.242, P = 0.039). Conclusions: Jihua Hemostatic Suppository exerts superior therapeutic and biochemical effects in hemorrhagic internal hemorrhoids compared with Gangtai Suppository. Its efficacy is likely mediated by suppression of the Xpo1/NF-kB inflammatory axis, inhibition of VEGF-driven angiogenesis, and normalization of collagen I/III-dependent extracellular matrix remodeling. These findings highlight the value of integrating biochemical biomarkers into clinical assessment of hemorrhoidal disease and suggest Xpo1, VEGF, and collagen I/III as potential molecular indicators of treatment efficacy.
Centre for Evaluation in Education and Science (CEON/CEES)
Title: Biochemical evaluation of Jihua hemostatic suppository in hemorrhagic internal hemorrhoids: Modulation of XPO1, VEGF, and collagen I/III expression and inflammatory biomarkers
Description:
Background: Hemorrhagic internal hemorrhoids involve abnormal vascular remodeling, inflammatory activation, and extracellular matrix dysregulation.
Exportin-1 (Xpo1), vascular endothelial growth factor (VEGF), and collagen types I and III are key biochemical markers associated with these processes.
This study aimed to evaluate the therapeutic efficacy of Jihua Hemostatic Suppository compared with Gangtai Suppository and to investigate their differential effects on biochemical and inflammatory parameters in patients with hemorrhagic internal hemorrhoids.
Methods: A total of 98 patients diagnosed with hemorrhagic internal hemorrhoids were enrolled between January 2024 and January 2025 and randomly divided into two groups (n = 49 each) using the envelope randomization method.
The Jihua group received Jihua Hemostatic Suppository, whereas the control group received Gangtai Suppository for two weeks.
Serum levels of interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), and C-reactive protein (CRP) were determined by ELISA.
Xpo1 levels were measured by ELISA, VEGF by chemiluminescence assay, and collagen types I and III by the hydroxyproline method.
Clinical efficacy, traditional Chinese medicine (TCM) syndrome scores, and adverse reactions were also recorded.
Results: The total effective rate in the Jihua group (93.
88% ) was significantly higher than that in the Gangtai group (77.
55% ) (c2 = 5.
968, P = 0.
015).
After treatment, the Jihua group showed markedly lower serum IL-6 (70.
50 ± 5.
82 ng/mL), CRP (23.
06 ± 2.
71 mg/L), and TNF-a (60.
81 ± 5.
72 ng/mL) levels compared with the Gangtai group (P < 0.
001).
Biochemically, Xpo1, VEGF, collagen I, and collagen III concentrations were significantly reduced in the Jihua group (12.
31 ± 1.
35 ng/mL, 389.
64 ± 34.
32 pg/mL, 154.
39 ± 15.
19 pg/L, and 36.
13 ± 3.
06 mg/L, respectively) compared with the Gangtai group (P < 0.
05).
The incidence of adverse reactions was lower with Jihua suppository (4.
08%) than with Gangtai suppository (20.
41% ) (c2 = 4.
242, P = 0.
039).
Conclusions: Jihua Hemostatic Suppository exerts superior therapeutic and biochemical effects in hemorrhagic internal hemorrhoids compared with Gangtai Suppository.
Its efficacy is likely mediated by suppression of the Xpo1/NF-kB inflammatory axis, inhibition of VEGF-driven angiogenesis, and normalization of collagen I/III-dependent extracellular matrix remodeling.
These findings highlight the value of integrating biochemical biomarkers into clinical assessment of hemorrhoidal disease and suggest Xpo1, VEGF, and collagen I/III as potential molecular indicators of treatment efficacy.
Related Results
Pharmacologic Inhibition of XPO1 By Selinexor Improves Late-Stage Erythropoiesis in Severely Affected β 0-Thalassemia/Hemoglobin E
Pharmacologic Inhibition of XPO1 By Selinexor Improves Late-Stage Erythropoiesis in Severely Affected β 0-Thalassemia/Hemoglobin E
Ineffective erythropoiesis due to accumulation of excess α-globin chains profounds unwarranted consequences in β-thalassemia. In severe β-thalassemia, the excess α-globin chains tr...
Abstract B055: XPO1-dependent nuclear export as a therapeutic target for ALK-positive non-small cell lung cancers
Abstract B055: XPO1-dependent nuclear export as a therapeutic target for ALK-positive non-small cell lung cancers
Abstract
EML4-ALK fusion has emerged as a significant oncogenic driver in Non-Small Cell Lung Cancer (NSCLC), promoting ...
Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas
Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas
C. Christov, H. Adle‐Biassette, C. Le Guerinel, S. Natchev and R. K. Gherardi (1998) Neuropathology and Applied Neurobiology24, 29–35Immunohistochemical detection of vascular endot...
Molecular Analysis of Vascular Endothelial Growth Factor (VEGF) Receptors in EUS-guided Samples Obtained from Patients with Pancreatic Adenocarcinoma*
Molecular Analysis of Vascular Endothelial Growth Factor (VEGF) Receptors in EUS-guided Samples Obtained from Patients with Pancreatic Adenocarcinoma*
Background & Aims: Vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1 and VEGF-R2) are the most important angiogenesis stimulating factors in pancreatic cance...
ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) IN PATHOGENESIS OF KNEE OSTEOARTHRITIS
ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) IN PATHOGENESIS OF KNEE OSTEOARTHRITIS
Recent evidences suggest that angiogenesis and inflammation contribute to the development and progression of knee osteoarthritis (OA). Vascular endothelial growth factor (VEGF) is ...
VEGF Receptor Signal Transduction
VEGF Receptor Signal Transduction
The family of vascular endothelial growth factors (VEGFs) currently includes VEGF-A, -B, -C, -D, -E, and placenta growth factor (PlGF). Several of these factors, notably VEGF-A, ex...
The correlation of MMP-9 and VEGF expressions towards nasopharyngeal angiofibroma clinical stage
The correlation of MMP-9 and VEGF expressions towards nasopharyngeal angiofibroma clinical stage
ABSTRACTBackground: Nasopharyngeal angiofibroma (NA) is a benign tumor with a destructive tendency, commonly affecting male adolescents. The management of NA could become quite a c...
Abstract 1580: Molecular mechanisms of OSM-induced VEGF in breast cancer
Abstract 1580: Molecular mechanisms of OSM-induced VEGF in breast cancer
Abstract
Oncostatin M (OSM) is an interleukin-6 (IL-6) family cytokine that has been shown to induce expression of vascular endothelial growth factor (VEGF) in astro...

